Showing results (191-200 of 824) with videos related to

Sort By:
Pageof 83
Immunotherapy|October 15, 2011
Intrinsic modulation of lymphocyte function by stromal cell network: advance in therapeutic targeting of cancerGüllü Görgün, Kenneth C Anderson
Blood|January 11, 2023
Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myelomaTing Du, Yan Song, Arghya Ray, et al.
Blood|May 19, 2007
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesisYu-Tzu Tai, Mariateresa Fulciniti, Teru Hideshima, et al.
Blood|March 29, 2024
Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myelomaAnnamaria Gulla, Eugenio Morelli, Megan Johnstone, et al.
Cancers|January 13, 2019
Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in OncogenesisMatthew Ho Zhi Guang, Emma L Kavanagh, Luke Paul Dunne, et al.
Clinical and Experimental Medicine|July 8, 2023
Characterizing dry mass and volume changes in human multiple myeloma cells upon treatment with proteotoxic and genotoxic drugsXili Liu, Maria Moscvin, Seungeun Oh, et al.
British Journal of Haematology|September 1, 2007
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cellsTeru Hideshima, Laurence Catley, Noopur Raje, et al.
Blood|January 14, 2017
p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myelomaTeru Hideshima, Francesca Cottini, Yoshihisa Nozawa, et al.
Cancer Cell|March 31, 2004
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumorsConstantine S Mitsiades, Nicholas S Mitsiades, Ciaran J McMullan, et al.
Oncogene|October 14, 2004
p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cellsTeru Hideshima, Klaus Podar, Dharminder Chauhan, et al.
Pageof 83